



DATROWAY® may be right for you if you are an adult with locally advanced* or metastatic[†] non-small cell lung cancer (NSCLC) that has certain mutations in a gene called epidermal growth factor receptor (EGFR) and who has received prior EGFR-directed medicine and platinum-based chemotherapy.

IGNITE YOUR FIGHT

*Has spread to areas outside of the lung.

[†]Has spread to other parts of the body.

Not an actual patient.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is DATROWAY®?

DATROWAY is a prescription medicine used to treat adults who have:

- non-small cell lung cancer (NSCLC) that has certain mutations in a gene called epidermal growth factor receptor (EGFR):
 - that has spread to areas outside of the lung (locally advanced) or has spread to other parts of the body (metastatic), and
 - who have received prior EGFR-directed medicine and platinum-based chemotherapy.

DATROWAY was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. DATROWAY is still being studied to confirm these results.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

It is not known if DATROWAY is safe and effective in children.

What is the most important information I should know about DATROWAY?

DATROWAY can cause serious side effects, including:

- Lung problems that may be severe, life-threatening, or that may lead to death. If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
 - cough
 - trouble breathing or shortness of breath
 - fever
 - other new or worsening breathing symptoms such as chest tightness or wheezing

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

WELCOME TO

DATROWAY®

datopotamab deruxtecan-dlnk

20 mg/mL INJECTION FOR INTRAVENOUS USE

A treatment for adults with EGFR-mutated non-small cell lung cancer (NSCLC) that is locally advanced* or metastatic† who have received prior EGFR-directed medicine and platinum-based chemotherapy.

Battling cancer requires courage, resilience, and the right information to help keep you moving forward.

*Has spread to areas outside of the lung.

†Has spread to other parts of the body.

EGFR=epidermal growth factor receptor.

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about DATROWAY? (cont'd)

- **Eye problems.** Eye problems are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop any new or worsening eye problems during treatment with DATROWAY, including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision or vision changes.
 - You should use preservative-free lubricating eye drops at least 4 times a day and as needed.
 - Do not wear contact lenses during treatment with DATROWAY unless your eye specialist tells you to.
 - Your healthcare provider will send you to an eye specialist to check your eyes when you start your treatment with DATROWAY, every year during treatment, at the end of treatment, and as needed for any new or worsening signs and symptoms of eye problems.

Table of contents

As you prepare to start DATROWAY, take a moment to review the information in this brochure with your care team and your care partner. Our goal is to help you feel more informed so you can begin treatment with confidence.

This DATROWAY (pronounced: DAT-roe-way) brochure includes:



HOW DATROWAY MAY WORK

PAGE 4



HOW DATROWAY IS GIVEN

PAGE 6



RESULTS WITH DATROWAY

PAGE 8



POSSIBLE SIDE EFFECTS

PAGE 11



MANAGING SELECT SIDE EFFECTS

PAGE 13



SUPPORT & RESOURCES

PAGE 15

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about DATROWAY? (cont'd)

- **Mouth ulcers and sores.** Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY.
 - Your healthcare provider will prescribe a steroid-containing mouthwash to use 4 times a day and as needed during treatment with DATROWAY.
 - You should hold ice chips or ice water in your mouth during your DATROWAY infusions.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.




DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE



| HOW DATROWAY MAY WORK

How DATROWAY is thought to work

DATROWAY is designed to release medicine at the right place, inside the cancer cell.



DATROWAY is designed to identify cancer cells that have Trop-2 (pronounced: trohp-too), a protein found on the surface of cancer cells.

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about DATROWAY? (cont'd)

Your healthcare provider will check you for these side effects during your treatment with DATROWAY. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with DATROWAY if you have severe side effects.


- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with DATROWAY.
 - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with DATROWAY.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including **WARNINGS AND PRECAUTIONS**, and Medication Guide.

DATROWAY[®]
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE


DATROWAY is designed to work in three steps

DATROWAY works by finding cancer cells that have Trop-2 so that it can attack and destroy them. Although DATROWAY is designed to target Trop-2 on cancer cells, it may affect some healthy cells. DATROWAY may not work for everyone.




IDENTIFY

First, DATROWAY looks for and attaches to Trop-2



INFILTRATE

It enters the cancer cell



DESTROY

Lastly, it releases medicine into the cancer cell that helps destroy it. It may also affect other surrounding cells, including healthy ones

Information from laboratory studies suggests that this is how DATROWAY works. The clinical relevance of these features is under investigation.

Trop-2=trophoblast cell-surface antigen 2.

IMPORTANT SAFETY INFORMATION (CONT'D)

What is the most important information I should know about DATROWAY? (cont'd)


- **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 7 months after the last dose.
- **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 4 months after the last dose.

See "What are the possible side effects of DATROWAY?" for more information about side effects.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

3 weeks between doses

Your month might look something like this while on DATROWAY:



- DATROWAY is given through an intravenous (IV) infusion
- You'll receive the IV infusion once every 3 weeks
- It will be given at your treatment center or doctor's office

Let your care team know if you need anything during your infusion days.



If you miss a planned dose of DATROWAY, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

IMPORTANT SAFETY INFORMATION (CONT'D)

Before receiving DATROWAY, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have eye problems.
- Use contact lenses.
- Are breastfeeding or plan to breastfeed. It is not known if DATROWAY passes into your breast milk. Do not breastfeed during treatment with DATROWAY and for 1 month after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

What to expect on DATROWAY treatment days



BEFORE INFUSION

You will be given medicines to help prevent nausea, vomiting, and infusion-related reactions.

NOTE: *There are measures you can take at home to help manage certain side effects such as mouth sores or eye problems. See [pages 13-14](#).*



YOUR FIRST INFUSION

It will take **90 minutes** to complete your first IV infusion. Once the infusion is finished, your care team will monitor you for **at least 1 hour** to see if you have any infusion-related reactions.

TIP: *Holding ice chips or ice water in your mouth throughout the infusion may help with mouth sores.*



FUTURE INFUSIONS

If you did not have any side effects after your first infusion, your infusions could last **30 minutes** each. Just like your first infusion, after your second infusion you will be monitored by your care team for **1 hour** to see if you have any infusion-related reactions. If you did not have any reactions after your second infusion, you will be monitored for **at least 30 minutes** after each following infusion.

REMEMBER: *Let your care team know if you're feeling any side effects. Please see [pages 11-12](#) for a select list of possible side effects.*

IMPORTANT SAFETY INFORMATION (CONT'D)

How will I receive DATROWAY?

- You will receive DATROWAY into your vein through an intravenous (IV) line by your healthcare provider.
- DATROWAY is usually given 1 time every three weeks (21-day treatment cycle).
- You will receive your first infusion over 90 minutes. If you do not have problems with your first infusion, you may receive your next infusions over 30 minutes.
- You will be monitored for side effects for at least 1 hour after your first 2 infusions. If you do not have problems after your second infusion, you will be monitored for at least 30 minutes after each following infusion.
- Your healthcare provider will decide how many treatments you need.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY was studied in clinical trials

DATROWAY was studied in adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has certain mutations in a gene called epidermal growth factor receptor (EGFR). The clinical trials included adults who received prior EGFR-directed medicine and platinum-based chemotherapy. Common platinum-based chemotherapy drugs include cisplatin and carboplatin.

DATROWAY was studied in two trials in patients with lung cancer. Only some of those patients in each trial had an EGFR mutation. Researchers studied the results in those patients with an EGFR mutation in both trials who took DATROWAY. They were studied as a group because their results represent a portion of all of the patients studied in each trial. The results don't represent all the patients in each trial.



The trials were held at multiple research sites

114

PEOPLE STUDIED

The analysis and FDA-approval was based on 114 people who had an EGFR mutation



Everyone had received prior treatments including an EGFR-directed medicine and platinum-based chemotherapy

36-81
AGE RANGE

In the clinical trials, the median age was 63 years. A median is the middle number in a set of numbers

DATROWAY was FDA-approved for this use based on clinical studies that measured how many patients responded and how long they responded. DATROWAY is still being studied to confirm these results.

Important to Note:

- The trials were open-label, meaning that both the people being treated and trial investigators knew which treatments were received. Therefore, the results could have been influenced by people switching to another treatment, leaving the study, or other factors
- There were 2 clinical trials. One of them was single-arm, which means that everyone enrolled in the study received DATROWAY. In that trial, DATROWAY was not compared to another medicine. In the other trial, DATROWAY was compared against docetaxel
- The results shown on the next 2 pages combine information from a group of patients in these 2 clinical trials and should be discussed with your doctor

IMPORTANT SAFETY INFORMATION (CONT'D)

How will I receive DATROWAY? (cont'd)


- Your healthcare provider will give you medicines before your infusion to help prevent nausea, vomiting, and infusion-related reactions.
- Your healthcare provider may slow down or temporarily stop your infusion of DATROWAY if you have an infusion-related reaction, or permanently stop DATROWAY if you have severe infusion reactions.
- If you miss a planned dose of DATROWAY, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

How many people had their tumors shrink

The trials measured the **overall response rate (tumor shrinking) results**. This is the percentage of people who had a partial or complete response to therapy. A complete response means the tumor could not be seen on imaging tests. A partial response means the tumor shrank by at least 30%.



45%* of people had their tumors shrink with DATROWAY

*51 of 114 people studied.

- 40% of people (46 out of 114) had a partial response, meaning their tumor shrank by at least 30%
- 4.4% of people (5 out of 114) had a complete response, meaning their tumor could not be seen on imaging tests

Important to Note:

- Please remember that the results you will see are from clinical trials, and each person's experience may differ. Speak with your doctor about what you may expect on DATROWAY treatment. DATROWAY was FDA-approved for this use based on clinical studies that measured how many patients responded and how long they responded. DATROWAY is still being studied to confirm these results
- DATROWAY was studied in 2 trials in patients with lung cancer. Only some of those patients in each trial had an EGFR mutation. Researchers studied the results in those patients with an EGFR mutation in both trials who took DATROWAY. They were studied as a group because their results represent a portion of all of the patients studied in each trial. The results don't represent all the patients in each trial

IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of DATROWAY?

DATROWAY can cause serious side effects, including:

- See "What is the most important information I should know about DATROWAY?"

The most common side effects of DATROWAY when used in adults with EGFR-mutated non-small cell lung cancer include:

• Nausea	• Tiredness	• Decreased white blood cell counts
• Hair loss	• Decreased red blood cell counts	

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

How long people continued to respond to treatment

The trials measured **median duration of response**, which is the length of time half of the people who responded to DATROWAY (complete or partial) continued to respond after the first response was seen. This means the length of time people's tumors continued to respond to treatment without growing or spreading. This was studied in 51 patients with an EGFR mutation who responded to DATROWAY.



IMPORTANT SAFETY INFORMATION (CONT'D)

What are the possible side effects of DATROWAY? (cont'd)

- Constipation
- Increased blood levels of calcium
- Increased blood levels of liver enzymes
- Increased levels of enzyme called lactate dehydrogenase in the blood
- Muscle and joint pain
- Rash
- Decreased appetite

DATROWAY may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of DATROWAY. Call your healthcare provider for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY can cause serious side effects

LUNG PROBLEMS

Lung problems that may be severe, life-threatening, or lead to death can occur with DATROWAY. If you develop lung problems, your doctor may treat you with corticosteroid medicines. Tell your care team right away if you have any of the following: cough, trouble breathing or shortness of breath, fever, or other new or worsening breathing symptoms such as chest tightness or wheezing.

EYE PROBLEMS

Eye problems are common with DATROWAY and can also be severe. Tell your care team right away if you develop any new or worsening eye problems during treatment with DATROWAY, including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision or vision changes.

MOUTH ULCERS AND SORES

Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your care team right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY.

HARM TO YOUR UNBORN BABY

DATROWAY may cause harm to your unborn baby. Tell your care team right away if you become pregnant or think you might be pregnant during treatment with DATROWAY.

- If you are able to become pregnant, your care team should do a pregnancy test before you start treatment
- Females who are able to become pregnant should use effective birth control (contraception) during treatment and for 7 months after the last dose
- Males who have partners who are able to become pregnant should use effective birth control (contraception) during treatment and for 4 months after the last dose

Please see pages 13-14 for important information on managing side effects.


This is not a complete list of symptoms for DATROWAY-associated side effects or all possible side effects of DATROWAY. Call your doctor for medical advice about symptoms or side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

Common side effects seen with DATROWAY

The majority of side effects in people who received DATROWAY were mild or moderate in severity for advanced or metastatic EGFR-mutated NSCLC.



Your doctor may reduce your dose of DATROWAY, interrupt treatment, or completely stop treatment if you have certain side effects




8% of people receiving DATROWAY discontinued treatment due to side effects

- Mild side effects may not affect your daily activities, and medical intervention may not be needed
- Moderate side effects may affect your daily activities and may require some medical intervention
- Severe side effects usually require medical intervention and may have serious or life-threatening consequences

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

Select side effects that may require treatment

Side effects or changes in the way you receive DATROWAY are possible, but following specific guidance may help you care for certain ones. Your healthcare provider will check you for these side effects during your treatment with DATROWAY. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with DATROWAY if you have certain side effects.



LUNG PROBLEMS

Lung problems that may be severe, life-threatening, or lead to death may occur while taking DATROWAY. If you develop lung problems, your doctor may treat you with corticosteroid medicines. Tell your care team right away if you get any of the following:

- Cough
- Trouble breathing or shortness of breath
- Fever
- Other new or worsening symptoms such as chest tightness or wheezing



EYE PROBLEMS

Eye problems are common with DATROWAY and can also be severe. Tell your care team right away if you develop any new or worsening eye problems including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision, or vision changes. While on DATROWAY, there is certain guidance you should follow:

- You should use preservative-free lubricating eye drops at least 4 times a day and as needed
- Do not wear contact lenses during treatment with DATROWAY unless your eye specialist tells you to
- Your doctor will send you to an eye specialist to check your eyes when you start your treatment with DATROWAY, every year during treatment, at the end of treatment, and as needed for any new or worsening signs and symptoms of eye problems



Remember to immediately report any and all side effects to your care team.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY[®]
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

Select side effects that may require treatment (cont'd)



MOUTH ULCERS AND SORES

Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY. To help care for them, your doctor will prescribe a steroid-containing mouthwash to use 4 times a day and as needed during treatment. Keep in mind:

- Work with your care team to make a mouthwash routine that you may follow and use as instructed
- Holding ice chips or ice water in your mouth during your DATROWAY infusions may help with mouth sores



NAUSEA AND VOMITING

Nausea and vomiting are possible, but this may help prevent them:

- Take anti-nausea medicine prescribed by your doctor before treatment and as needed after treatment



For more information on addressing side effects, visit DATROWAY.com

DATROWAY4U: Treatment support

DATROWAY4U has programs that may help you access and afford your prescribed DATROWAY treatment, including benefit reviews, prior authorizations, claims appeals, and paying for your prescription.



DATROWAY4U may help you understand your insurance coverage. Knowing this information may simplify the process of getting your prescription.



The DATROWAY Patient Savings Program may help you with out-of-pocket costs if you are commercially insured. There are no income requirements to participate.



DATROWAY4U is designed to help insured, uninsured, and underinsured people access treatment.

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE



Visit DATROWAY4U.com or call
1-855-DATRO4U (1-855-328-7648)
to learn more

Please see the complete [Important Safety Information](#) on pages 17-18, the [full Prescribing Information](#), including **WARNINGS AND PRECAUTIONS**, and [Medication Guide](#).

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

Support from the community



CANCER.ORG

The American Cancer Society is a leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. They are the only organization working to improve the lives of people with cancer and their families through advocacy, research, and patient support, to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.



LUNG.ORG

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.



GO2FOUNDATION.ORG

GO2 for Lung Cancer relentlessly confronts lung cancer on every front, every day, for everyone. Founded by patients and survivors in 1995, they are dedicated to increasing survival and quality of life for those at risk, diagnosed, and living with lung cancer.



LUNGCANCERRESEARCHFOUNDATION.ORG

The Lung Cancer Research Foundation's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer.



LUNGCANCER.ORG

LUNGevity is the leading nonprofit that's transforming how people are diagnosed and live with lung cancer through research, education, and support.

This is not an all-inclusive list of resources.

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including WARNINGS AND PRECAUTIONS, and Medication Guide.

DATROWAY
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

INDICATION AND IMPORTANT SAFETY INFORMATION

What is DATROWAY®?

DATROWAY is a prescription medicine used to treat adults who have:

- non-small cell lung cancer (NSCLC) that has certain mutations in a gene called epidermal growth factor receptor (EGFR):
 - that has spread to areas outside of the lung (locally advanced) or has spread to other parts of the body (metastatic), **and**
 - who have received prior EGFR-directed medicine and platinum-based chemotherapy.

DATROWAY was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. DATROWAY is still being studied to confirm these results.

It is not known if DATROWAY is safe and effective in children.

What is the most important information I should know about DATROWAY?

DATROWAY can cause serious side effects, including:

- **Lung problems that may be severe, life-threatening, or that may lead to death.** If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
 - cough
 - trouble breathing or shortness of breath
 - fever
 - other new or worsening breathing symptoms such as chest tightness or wheezing
- **Eye problems.** Eye problems are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop any new or worsening eye problems during treatment with DATROWAY, including dry eyes, eye pain, eye redness, eye swelling, eye irritation, increased tears, feeling like something is in your eyes, discharge from your eyes, eye crusting, sensitivity to light, blurred vision or vision changes.
 - You should use preservative-free lubricating eye drops at least 4 times a day and as needed.
 - Do not wear contact lenses during treatment with DATROWAY unless your eye specialist tells you to.
 - Your healthcare provider will send you to an eye specialist to check your eyes when you start your treatment with DATROWAY, every year during treatment, at the end of treatment, and as needed for any new or worsening signs and symptoms of eye problems.
- **Mouth ulcers and sores.** Mouth ulcers and sores are common with DATROWAY and can also be severe. Tell your healthcare provider right away if you develop mouth pain, swelling, redness, ulcers, or sores during treatment with DATROWAY.
 - Your healthcare provider will prescribe a steroid-containing mouthwash to use 4 times a day and as needed during treatment with DATROWAY.
 - You should hold ice chips or ice water in your mouth during your DATROWAY infusions.

Your healthcare provider will check you for these side effects during your treatment with DATROWAY. Your healthcare provider may reduce your dose, delay treatment, or completely stop treatment with DATROWAY if you have severe side effects.

- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with DATROWAY.
 - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with DATROWAY.
 - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 7 months after the last dose.

Please see the complete **Important Safety Information** on pages 17-18, the **full Prescribing Information**, including **WARNINGS AND PRECAUTIONS**, and **Medication Guide**.

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

INDICATION AND IMPORTANT SAFETY INFORMATION (CONT'D)

- **Males** who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with DATROWAY and for 4 months after the last dose.

See “What are the possible side effects of DATROWAY?” for more information about side effects.

Before receiving DATROWAY, tell your healthcare provider about all of your medical conditions, including if you:

- Have lung or breathing problems.
- Have eye problems.
- Use contact lenses.
- Are breastfeeding or plan to breastfeed. It is not known if DATROWAY passes into your breast milk. Do not breastfeed during treatment with DATROWAY and for 1 month after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive DATROWAY?

- You will receive DATROWAY into your vein through an intravenous (IV) line by your healthcare provider.
- DATROWAY is usually given 1 time every three weeks (21-day treatment cycle).
- You will receive your first infusion over 90 minutes. If you do not have problems with your first infusion, you may receive your next infusions over 30 minutes.
- You will be monitored for side effects for at least 1 hour after your first 2 infusions. If you do not have problems after your second infusion, you will be monitored for at least 30 minutes after each following infusion.
- Your healthcare provider will decide how many treatments you need.
- Your healthcare provider will give you medicines before your infusion to help prevent nausea, vomiting, and infusion-related reactions.
- Your healthcare provider may slow down or temporarily stop your infusion of DATROWAY if you have an infusion-related reaction, or permanently stop DATROWAY if you have severe infusion reactions.
- If you miss a planned dose of DATROWAY, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

What are the possible side effects of DATROWAY?

DATROWAY can cause serious side effects, including:

- See "What is the most important information I should know about DATROWAY?"

The most common side effects of DATROWAY when used in adults with EGFR-mutated non-small cell lung cancer include:

• Nausea	• Constipation	lactate dehydrogenase in the blood
• Hair loss	• Increased blood levels of calcium	• Muscle and joint pain
• Tiredness	• Increased blood levels of liver enzymes	• Rash
• Decreased red blood cell counts	• Increased levels of enzyme called	• Decreased appetite
• Decreased white blood cell counts		

DATROWAY may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of DATROWAY. Call your healthcare provider for medical advice about side effects. You may report side effects to Daiichi Sankyo at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see the complete **Important Safety Information** on pages 17-18, the **full Prescribing Information**, including **WARNINGS AND PRECAUTIONS**, and **Medication Guide**.

DATROWAY
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE

Key reminder about treatment with DATROWAY



DATROWAY is given through an IV infusion **once every 3 weeks** and takes **90 minutes** to administer your first dose. If you do not have any infusion-related reactions during your first treatment, your infusions could be as short as **30 minutes**.



DATROWAY4U is available to help you access and afford your prescribed DATROWAY treatment.*

*Eligibility required.



Stay informed about your treatment. Visit DATROWAY.com to learn more about DATROWAY and explore resources available for you and your family.

What is DATROWAY®?

DATROWAY is a prescription medicine used to treat adults who have:

- non-small cell lung cancer (NSCLC) that has certain mutations in a gene called epidermal growth factor receptor (EGFR):
 - that has spread to areas outside of the lung (locally advanced) or has spread to other parts of the body (metastatic), **and**
 - who have received prior EGFR-directed medicine and platinum-based chemotherapy.

DATROWAY was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. DATROWAY is still being studied to confirm these results.

It is not known if DATROWAY is safe and effective in children.

What is the most important information I should know about DATROWAY?

DATROWAY can cause serious side effects, including:

- Lung problems that may be severe, life-threatening, or that may lead to death. If you develop lung problems, your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms:
 - cough
 - trouble breathing or shortness of breath
 - fever
 - other new or worsening breathing symptoms such as chest tightness or wheezing

Please see the complete Important Safety Information on pages 17-18, the full Prescribing Information, including **WARNINGS AND PRECAUTIONS**, and Medication Guide.



DATROWAY® is a registered trademark of Daiichi Sankyo Company, Limited.
© 2025 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-DTL-0318 11/25

DATROWAY®
datopotamab deruxtecan-dlnk
20 mg/mL INJECTION FOR INTRAVENOUS USE